RTP Mobile Logo
Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Multiple Myeloma (Faculty Presentations)
Released March 2021

Featuring slide presentations and related discussion from Drs Rafael Fonseca and Jonathan L Kaufman. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.


    • Customize induction and subsequent maintenance therapeutic approaches for individuals with multiple myeloma (MM) eligible or ineligible for stem cell transplant, considering recently presented clinical trial findings and patient- and disease-related factors, including cytogenetic profile.
    • Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
    • Evaluate research data with the use of minimal residual disease (MRD) status to predict long-term outcomes with therapy, and apply this information to determine the current and potential role of MRD testing in protocol and nonresearch management of MM.
    • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with selinexor for previously treated MM, and identify patients for whom treatment with this novel compound is appropriate.
    • Recognize the available research data leading to the FDA approval of isatuximab in combination with pomalidomide/dexamethasone for relapsed/refractory MM, and discern how this agent should be effectively integrated into current clinical algorithms.
    • Recall the biologic rationale for targeting the B-cell maturation antigen (BCMA) with novel therapies in MM, and recognize the similarities and differences between the various investigational products.
    • Appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at BCMA, and identify patients with relapsed/refractory MM for whom this approach may be appropriate as part of a clinical research study.
    • Understand the mechanism of action of and pivotal clinical trial findings with belantamab mafodotin for previously treated MM in preparation for the potential availability of this novel compound.
    • Assess the mechanisms of action, available data and ongoing clinical trials with other novel, investigational approaches for MM, and counsel appropriately selected patients about participation in active research protocols.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Director for Innovation and Transformational Relationships
    Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
    Chair, Department of Internal Medicine
    Distinguished Mayo Investigator
    Mayo Clinic in Arizona
    Phoenix, Arizona

    Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology.

    Jonathan L Kaufman, MD
    Associate Professor of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Tecnofarma; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Fortis Therapeutics, Janssen Biotech Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Oncopeptides and Takeda Oncology.

    Release date: March 2021
    Expiration date: March 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):